Stock listing
BX Swiss:NG9 NeoGenomics, Inc. Aktie
Swiss listing (BX Swiss) of NeoGenomics, Inc. · home listing NASDAQ:NEO
Follow NeoGenomics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:NEO
$14.82 USD -0.47 (-3.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:NEO
- Day range
- $14.63 – $15.14 USDNov 20, 2026
- Volume
- 1.18M sharesNov 20, 2026
- Market cap
- $1.92B USDAt the close on Nov 20, 2026 · price × 129.4M shares outstanding
- 52-week range
- $7.07 – $20.15 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $34.37M USDMedian day 1.62M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NEO · Home | $14.82 USD | -0.47 (-3.1%) | 1,177,080 | $14.86 | $15.14 | $14.63 | $15.29 | Close on Nov 20, 2026 |
| Frankfurt:NG9 | €13.54 EUR | -0.325 (-2.3%) | — | €13.54 | €13.54 | €13.54 | €13.87 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NEO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $14.82 | -0.47 | -3.1% | $14.86 | $15.14 | $14.63 | 1,177,080 | |
| $15.29 | +0.04 | +0.3% | $15.23 | $15.51 | $14.86 | 1,090,804 | |
| $15.25 | -0.16 | -1.0% | $15.60 | $15.60 | $14.97 | 1,033,361 | |
| $15.41 | -0.61 | -3.8% | $15.75 | $15.78 | $15.36 | 1,174,016 | |
| $16.02 | -0.52 | -3.1% | $16.50 | $16.50 | $15.67 | 2,217,573 | |
| $16.54 | -0.29 | -1.7% | $16.45 | $16.69 | $16.11 | 1,353,151 | |
| $16.83 | -0.13 | -0.8% | $17.02 | $17.67 | $16.75 | 957,230 | |
| $16.96 | -0.64 | -3.6% | $17.42 | $17.59 | $16.83 | 1,758,989 | |
| $17.60 | +0.76 | +4.5% | $17.01 | $17.65 | $16.87 | 1,162,774 | |
| $16.84 | +0.35 | +2.1% | $16.85 | $16.93 | $16.12 | 1,314,036 | |
| $16.49 | -0.66 | -3.8% | $16.90 | $16.90 | $15.90 | 2,105,347 | |
| $17.15 | +0.32 | +1.9% | $17.26 | $17.39 | $16.60 | 1,149,921 | |
| $16.83 | +0.34 | +2.1% | $16.65 | $17.34 | $16.57 | 1,809,799 | |
| $16.49 | -0.89 | -5.1% | $17.66 | $17.66 | $16.29 | 1,706,037 | |
| $17.38 | -0.55 | -3.1% | $17.95 | $18.14 | $17.09 | 1,463,704 | |
| $17.93 | -0.06 | -0.3% | $17.25 | $18.15 | $16.83 | 3,758,968 | |
| $17.99 | +0.72 | +4.2% | $17.30 | $18.03 | $17.25 | 2,575,016 | |
| $17.27 | +0.58 | +3.5% | $16.91 | $17.48 | $16.69 | 2,753,347 | |
| $16.69 | +0.10 | +0.6% | $16.82 | $17.00 | $16.61 | 1,302,408 | |
| $16.59 | +0.20 | +1.2% | $16.36 | $16.76 | $16.07 | 1,431,500 | |
| $16.39 | -0.65 | -3.8% | $16.89 | $17.17 | $16.13 | 2,463,400 | |
| $17.04 | +0.42 | +2.5% | $16.62 | $17.30 | $16.54 | 1,493,600 | |
| $16.62 | +0.20 | +1.2% | $16.55 | $16.92 | $16.39 | 1,103,000 | |
| $16.42 | -0.23 | -1.4% | $16.90 | $17.17 | $16.39 | 1,332,300 | |
| $16.65 | -0.60 | -3.5% | $17.24 | $17.45 | $16.44 | 2,308,900 | |
| $17.25 | +0.37 | +2.2% | $17.00 | $17.34 | $16.61 | 1,315,000 | |
| $16.88 | +0.22 | +1.3% | $16.49 | $17.25 | $16.45 | 1,615,900 | |
| $16.66 | +0.46 | +2.8% | $16.30 | $16.98 | $15.98 | 2,233,100 | |
| $16.20 | -0.15 | -0.9% | $16.35 | $16.35 | $15.86 | 1,183,600 | |
| $16.35 | +0.33 | +2.1% | $16.02 | $16.66 | $16.00 | 1,385,300 | |
| $16.02 | +0.05 | +0.3% | $15.72 | $16.09 | $15.41 | 3,518,300 | |
| $15.97 | -0.54 | -3.3% | $16.36 | $16.64 | $15.88 | 3,191,900 | |
| $16.51 | -2.62 | -13.7% | $20.00 | $20.15 | $16.47 | 5,097,500 | |
| $19.13 | +0.66 | +3.6% | $18.48 | $19.13 | $18.28 | 2,048,900 | |
| $18.47 | +0.69 | +3.9% | $17.99 | $18.69 | $17.94 | 2,302,400 | |
| $17.78 | -0.58 | -3.2% | $18.18 | $18.76 | $17.74 | 2,470,000 | |
| $18.36 | -0.38 | -2.0% | $18.76 | $18.97 | $18.28 | 2,473,600 | |
| $18.74 | -0.55 | -2.9% | $19.30 | $19.75 | $18.58 | 2,695,600 | |
| $19.29 | -0.04 | -0.2% | $19.02 | $19.59 | $19.01 | 1,299,100 | |
| $19.33 | -0.23 | -1.2% | $19.56 | $19.75 | $18.87 | 2,019,600 | |
| $19.56 | +1.20 | +6.5% | $18.47 | $19.73 | $18.40 | 2,948,600 | |
| $18.36 | -0.53 | -2.8% | $18.69 | $19.08 | $18.27 | 2,911,400 | |
| $18.89 | -0.52 | -2.7% | $19.28 | $19.60 | $18.83 | 4,000,500 | |
| $19.41 | -0.50 | -2.5% | $19.92 | $20.05 | $19.28 | 1,435,100 | |
| $19.91 | +0.02 | +0.1% | $19.91 | $20.03 | $19.40 | 4,398,200 | |
| $19.89 | +0.95 | +5.0% | $19.11 | $19.89 | $18.98 | 2,006,600 | |
| $18.94 | +0.05 | +0.3% | $18.84 | $19.38 | $18.77 | 1,621,200 | |
| $18.89 | +0.48 | +2.6% | $18.40 | $19.29 | $18.40 | 2,425,400 | |
| $18.41 | +1.09 | +6.3% | $17.36 | $18.49 | $17.36 | 1,501,500 | |
| $17.32 | -0.29 | -1.6% | $17.85 | $17.92 | $17.21 | 1,072,000 | |
| $17.61 | -0.05 | -0.3% | $17.46 | $17.75 | $17.31 | 1,111,700 | |
| $17.66 | +0.10 | +0.6% | $17.28 | $18.00 | $17.15 | 1,541,600 | |
| $17.56 | +0.18 | +1.0% | $17.15 | $17.84 | $16.95 | 1,147,700 | |
| $17.38 | -0.08 | -0.5% | $17.20 | $17.47 | $16.87 | 996,900 | |
| $17.46 | +0.06 | +0.3% | $17.50 | $17.90 | $17.05 | 2,247,400 | |
| $17.40 | -0.05 | -0.3% | $17.40 | $18.18 | $17.26 | 1,794,500 | |
| $17.45 | -0.46 | -2.6% | $17.67 | $18.11 | $17.36 | 1,317,700 | |
| $17.91 | -0.14 | -0.8% | $17.77 | $18.08 | $17.19 | 1,579,100 | |
| $18.05 | -0.59 | -3.2% | $18.36 | $18.75 | $17.89 | 1,723,900 | |
| $18.64 | +1.27 | +7.3% | $17.85 | $19.76 | $17.85 | 5,098,000 | |
| $17.37 | +0.58 | +3.5% | $16.69 | $17.46 | $16.58 | 1,679,900 | |
| $16.79 | +0.38 | +2.3% | $16.70 | $16.90 | $16.37 | 872,100 | |
| $16.41 | -0.57 | -3.4% | $16.75 | $16.80 | $16.28 | 1,093,900 | |
| $16.98 | +0.45 | +2.7% | $16.60 | $17.08 | $16.21 | 1,139,800 | |
| $16.53 | -0.13 | -0.8% | $16.18 | $16.82 | $15.98 | 2,748,100 |
Splits
2 splits since 2000 · NASDAQ:NEO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-100 | Consolidation | |
| 4-for-1 | Split |
- Ticker
- BX Swiss:NG9
- Asset type
- Stock
- Exchange
- BX Swiss
- Currency
- CHF
What changed lately
Latest news release · Nov 6, 2026
NeoGenomics to Participate in Upcoming Investor Conferences
Latest earnings call · Oct 28, 2026
NeoGenomics (NASDAQ:NEO) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 28, 2026
Q3 2026 Earnings Presentation
Earnings · 26 slides
Latest news
NeoGenomics to Participate in Upcoming Investor Conferences
Nov 6, 2026
Closed $16.84 (+2.1%) on Nov 6, 2026
NeoGenomics Reports Third Quarter 2026 Results
Oct 28, 2026
Closed $17.93 (-0.3%) on Oct 29, 2026
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
Oct 15, 2026
Closed $17.25 (+2.2%) on Oct 15, 2026
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
Oct 14, 2026
Closed $16.88 (+1.3%) on Oct 14, 2026
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
Oct 5, 2026
Closed $16.51 (-13.7%) on Oct 6, 2026
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Sep 1, 2026
Closed $17.45 (-2.6%) on Sep 1, 2026
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
Aug 26, 2026
Closed $18.64 (+7.3%) on Aug 27, 2026
NeoGenomics Reports Second Quarter 2026 Results
Jul 28, 2026
Closed $15.27 (+14.0%) on Jul 29, 2026
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
Jul 20, 2026
Closed $14.45 (+1.5%) on Jul 21, 2026
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
Jul 9, 2026
Closed $14.73 (+3.4%) on Jul 9, 2026
NeoGenomics, Inc. on 6ix
- News releases
- 30 in the last 12 months · 212 in all · newest Nov 6, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Oct 28, 2026
- Decks
- 44 decks · latest Oct 28, 2026
Where NeoGenomics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NEO · Home listing | NASDAQ | United States | USD |
| BMV:NEO | BMV | Mexico | MXN |
| LS Exchange:120159 | LS Exchange | Germany | EUR |
| gettex:NG9 | gettex | Germany | EUR |
| Lang & Schwarz:120159 | Lang & Schwarz | Germany | EUR |
| BIVA:NEO | BIVA | Mexico | MXN |
| BOATS:NEO | BOATS | United States | USD |
| BX Swiss:NG9 · This page | BX Swiss | Switzerland | CHF |
| Dusseldorf:NG9 | Dusseldorf | Germany | EUR |
| Frankfurt:NG9 | Frankfurt | Germany | EUR |
| Munich:NG9 | Munich | Germany | EUR |
| Stuttgart:NG9 | Stuttgart | Germany | EUR |
| Tradegate:NG9 | Tradegate | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.15B USD
- P/E
- Loss
- EV/sales
- 2.7×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 2.4×
- Gross margin
- 44.8%
- Operating margin
- −6.3%
- Net margin
- −4.1%
- Debt to equity
- 0.5×
- Beta vs S&P 500
- 1.05
Forecasts
6 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 23.40 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.20 · 10 analysts
- Revenue, year to Dec 2026
- 808.2M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Tony Zook | Chief Executive Officer |
| Abhishek Jain | Chief Financial Officer |
| Warren Stone | President and Chief Operating Officer |
| Ellisa Cholapranee | General Counsel |
| Clarence Cooper | Vice President, Compliance & Privacy |
| Nate Montgomery | Vice President, Medical Services |
| Andrew Lukowiak | Chief Innovation Officer |
| Elizabeth Floegel | Chief Digital and Information Officer |
| Gary Passman | Chief Culture Officer |
| Kristi McKeown | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Lynn A. Tetrault | Chair of the Board |
| Carolyn Starrett | Board Member |
| David Perez | Board Member |
| Felicia Williams | Board Member |
| Jack Kenny | Board Member |
| Marjorie Green | Board Member |
| Michael A. Kelly | Board Member |
| Neil Gunn | Board Member |
| Stephen M. Kanovsky | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| NeoGenomics (NASDAQ:NEO) Q3 2026 Earnings Call | Wed, Oct 28, 2026 · 4:30 PM ET | Replay |
| NeoGenomics (NASDAQ:NEO) Q2 2026 Earnings Call | Tue, Jul 28, 2026 · 4:30 PM ET | Replay |
| NeoGenomics (NASDAQ:NEO) Q1 2026 Earnings Call | Tue, Apr 28, 2026 · 4:30 PM ET | Replay |
| NeoGenomics (NASDAQ:NEO) Q4 2025 Earnings Call | Tue, Feb 17, 2026 · 8:30 AM ET | Replay |
| NeoGenomics (NASDAQ:NEO) Q3 2025 Earnings Call | Tue, Oct 28, 2025 · 8:30 AM ET | Replay |
| NeoGenomics (NASDAQ:NEO) Q2 2025 Earnings Call | Tue, Jul 29, 2025 · 8:30 AM ET | Replay |
| NeoGenomics (NASDAQ:NEO) Q1 2025 Earnings Call | Tue, Apr 29, 2025 · 8:30 AM ET | Replay |
| NeoGenomics (NASDAQ:NEO) Q4 2024 Earnings Call | Tue, Feb 18, 2025 · 8:30 AM ET | Replay |
| NeoGenomics (NASDAQ:NEO) Q3 2024 Earnings Call | Tue, Nov 05, 2024 · 8:30 AM ET | Replay |
| NeoGenomics (NASDAQ:NEO) Q2 2024 Earnings Call | Mon, Jul 29, 2024 · 4:30 PM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 28, 2026 · After close | −0.3% |
| Q2 2026 | Jul 28, 2026 · After close | +14.0% |
| Q1 2026 | May 5, 2026 | −1.2% |
| Q4 2025 | Feb 17, 2026 · Before open | +0.5% |
| Q3 2025 | Oct 28, 2025 · Before open | −2.4% |
| Q2 2025 | Jul 29, 2025 · Before open | −18.7% |
| Q1 2025 | Apr 29, 2025 · Before open | −34.0% |
| Q4 2024 | Feb 18, 2025 · Before open | −14.0% |
| Q3 2024 | Nov 5, 2024 · Before open | +5.6% |
| Q2 2024 | Jul 29, 2024 · After close | +18.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 30, 2024 · Before open | −8.5% |
| Q4 2023 | Feb 20, 2024 · After close | +12.1% |
| Q3 2023 | Nov 6, 2023 · After close | +14.2% |
| Q2 2023 | Aug 8, 2023 · Before open | −3.0% |
| Q1 2023 | May 8, 2023 · After close | +18.5% |
| Q4 2022 | Feb 23, 2023 · Before open | +24.6% |
| Q3 2022 | Nov 8, 2022 · Before open | +25.4% |
| Q2 2022 | Aug 9, 2022 · Before open | +14.2% |
| Q1 2022 | Apr 27, 2022 · Before open | −3.8% |
| Q4 2021 | Feb 23, 2022 · Before open | −1.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 26 slides | Oct 28, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 24 slides | Jul 28, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 27 slides | Apr 28, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 15 slides | Feb 17, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 17 slides | Oct 28, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 17 slides | Jul 29, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 19 slides | Apr 29, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 25 slides | Feb 18, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 25 slides | Nov 5, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 30 slides | Jul 29, 2024 |
All 44 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 2024 Earnings Presentation | Earnings | 22 slides | Apr 30, 2024 |
| Q4 2023 Earnings Presentation | Earnings | 27 slides | Feb 20, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 23 slides | Nov 6, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 25 slides | Aug 8, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 24 slides | May 8, 2023 |
| Investor Day (April 2023) | Investor day | 79 slides | Apr 4, 2023 |
| Technical Presentation (November 2021) | Technical | 11 slides | November 2021 |
| Investor Presentation (August 2021) | Investor deck | 37 slides | Aug 10, 2021 |
| Investor Presentation (May 2021) | Investor deck | 35 slides | May 6, 2021 |
| Investor Presentation (October 2020) | Investor deck | 26 slides | Oct 29, 2020 |
| Investor Presentation (July 2020) | Investor deck | 26 slides | Jul 31, 2020 |
| Investor Presentation (March 2020) | Investor deck | 29 slides | Mar 2, 2020 |
| ASH 2020 | Conference | 11 slides | 2020 |
| Technical Presentation (2020) | Technical | 10 slides | 2020 |
| Technical Presentation (2020) | Technical | 8 slides | 2020 |
| Investor Presentation (October 2019) | Investor deck | 29 slides | Oct 31, 2019 |
| Investor Presentation (August 2019) | Investor deck | 30 slides | Aug 2, 2019 |
| IPO Roadshow (May 2019) | IPO roadshow | 29 slides | May 20, 2019 |
| Investor Presentation (May 2019) | Investor deck | 31 slides | May 2, 2019 |
| Investor Presentation (February 2019) | Investor deck | 33 slides | Feb 21, 2019 |
| Investor Presentation (November 2018) | Investor deck | 32 slides | Nov 7, 2018 |
| Merger or Acquisition (October 2018) | Merger or acquisition | 11 slides | Oct 23, 2018 |
| IPO Roadshow (August 2018) | IPO roadshow | 33 slides | Aug 6, 2018 |
| Investor Presentation (June 2018) | Investor deck | 38 slides | Jun 12, 2018 |
| Investor Presentation (May 2018) | Investor deck | 35 slides | May 25, 2018 |
| Investor Day (May 2017) | Investor day | 121 slides | May 30, 2017 |
| Shareholder Meeting (June 2016) | Shareholder meeting | 26 slides | Jun 8, 2016 |
| Merger or Acquisition (December 2015) | Merger or acquisition | 29 slides | Dec 23, 2015 |
| Merger or Acquisition (December 2015) | Merger or acquisition | 26 slides | Dec 17, 2015 |
| Merger or Acquisition (October 2015) | Merger or acquisition | 20 slides | Oct 21, 2015 |
| Investor Presentation (February 2013) | Investor deck | 20 slides | February 2013 |
| Investor Presentation (January 2013) | Investor deck | 18 slides | January 2013 |
| Investor Presentation (April 2012) | Investor deck | 19 slides | April 2012 |
| Investor Presentation (November 2011) | Investor deck | 19 slides | November 2011 |
Financings
| Raise | Date |
|---|---|
| 0.75% convertible senior notes due 2032 Update: US$275M Use of proceeds: About $25 million of net proceeds to pay the cost of capped call transactions | Jun 17, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 727.3M | 660.6M | 591.6M | 509.7M | 484.3M | 444.4M | 408.8M | 276.7M | 240.3M | 231.8M |
| Cost of revenue | 413.0M | 370.5M | 347.0M | 321.8M | 297.3M | 258.6M | 212.0M | 149.5M | 138.3M | 133.7M |
| Gross profit | 314.3M | 290.1M | 244.6M | 187.9M | 187.1M | 185.9M | 196.8M | 127.3M | 102.0M | 98.1M |
| Research and development | 37.1M | 31.2M | 27.3M | 30.3M | 21.9M | 8.23M | 8.49M | 3.00M | 3.64M | 4.65M |
| Operating income | -115.9M | -92.1M | -107.7M | -157.6M | -118.8M | -14.0M | 13.0M | 10.0M | 2.90M | 2.15M |
| Depreciation and amortization | 36.1M | 39.1M | 37.5M | 35.4M | 30.2M | 25.9M | 20.3M | 15.8M | 15.6M | 15.9M |
| EBITDA | -79.8M | -53.0M | -70.3M | -122.3M | -88.6M | 11.9M | 33.4M | 25.8M | 18.5M | 18.1M |
| Interest expense | 3.75M | 6.62M | 6.91M | 7.58M | 8.22M | 7.02M | 3.71M | 6.23M | 5.54M | |
| Income before tax | -110.3M | -80.7M | -97.1M | -159.3M | -15.1M | -14.1M | 3.65M | 3.82M | -2.65M | -7.84M |
| Income tax | -2.24M | -1.95M | -9.13M | -15.1M | -6.73M | -18.2M | -4.36M | 1.18M | -2.25M | -1.70M |
| Net income | -108.0M | -78.7M | -88.0M | -144.3M | -8.35M | 4.17M | 8.01M | 2.64M | -396.0K | -6.14M |
| Earnings per share, basic | -0.84 | -0.61 | -0.69 | -1.14 | -0.07 | 0.04 | 0.08 | 0.03 | -0.00 | -0.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 159.6M | 367.0M | 342.5M | 263.2M | 316.8M | 228.7M | 173.0M | 9.81M | 12.8M | 12.5M |
| Short-term investments | 198.6M | 67.5M | 0 | |||||||
| Receivables | 159.2M | 150.5M | 131.2M | 119.7M | 112.1M | 106.8M | 94.2M | 76.9M | 60.4M | 55.5M |
| Inventory | 28.6M | 26.7M | 24.2M | 24.3M | 23.4M | 29.5M | 14.4M | 8.65M | 7.47M | 6.25M |
| Current assets | 376.3M | 596.0M | 596.8M | 605.3M | 681.5M | 448.7M | 290.7M | 103.7M | 85.9M | 78.8M |
| Property, plant and equipment | 84.8M | 94.1M | 92.0M | 102.5M | 109.5M | 85.9M | 64.2M | 60.9M | 36.5M | 34.0M |
| Goodwill | 524.3M | 522.8M | 522.8M | 522.8M | 527.1M | 211.1M | 198.6M | 197.9M | 147.0M | 147.0M |
| Total assets | 1.36B | 1.64B | 1.68B | 1.74B | 1.87B | 988.3M | 709.5M | 505.0M | 344.5M | 337.1M |
| Accounts payable | 23.1M | 21.6M | 20.3M | 20.5M | 17.9M | 25.0M | 19.6M | 17.8M | 10.4M | 16.8M |
| Current liabilities | 88.3M | 301.2M | 96.3M | 89.9M | 87.2M | 73.2M | 63.9M | 60.9M | 36.5M | 38.1M |
| Long-term debt | 341.9M | 340.3M | 538.2M | 535.3M | 532.6M | 169.1M | 95.0M | 92.9M | 91.1M | 91.9M |
| Total debt | 341.9M | 541.1M | 538.2M | 70.0K | 1.14M | 0 | 5.00M | 101.8M | 96.7M | 97.9M |
| Total liabilities | 523.3M | 735.7M | 739.7M | 742.0M | 761.5M | 294.0M | 202.1M | 184.6M | 139.9M | 150.5M |
| Shareholders' equity | 836.6M | 902.3M | 941.5M | 998.0M | 1.11B | 694.3M | 507.4M | 320.4M | 172.0M | 162.3M |
| Shares outstanding | 129.0M | 128.1M | 127.4M | 126.9M | 124.1M | 112.1M | 104.8M | 94.5M | 80.5M | 78.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 5.23M | 7.02M | -1.95M | -66.0M | -26.7M | 1.46M | 23.4M | 44.8M | 18.0M | 21.5M |
| Capital spending | -27.0M | -41.1M | -28.8M | -30.9M | -64.1M | -29.1M | -20.0M | -14.3M | -13.7M | -7.54M |
| Free cash flow | -21.8M | -34.0M | -30.7M | -96.9M | -90.9M | -27.6M | 3.34M | 30.5M | 4.35M | 13.9M |
| Cash from investing | -12.3M | 12.9M | 76.7M | 517.0K | -632.4M | -159.4M | -19.6M | -139.7M | -13.7M | -6.50M |
| Cash from financing | -200.3M | 4.65M | 4.55M | 11.8M | 725.3M | 235.6M | 159.5M | 92.0M | -4.09M | -25.9M |
| Change in cash | -207.4M | 24.5M | 79.3M | -53.6M | 66.2M | 77.6M | 163.2M | -3.01M | 296.0K | -10.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 5, 2026 | Results | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 25, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 25, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 11, 2026 | Management or board change | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 30, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Jul 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 28, 2026 | Results | SEC |
| 8-K/A · Current report, amended | Jul 22, 2026 | Current report | SEC |
| 8-K · Current report | Jul 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 22, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2026 | Current report | SEC |
| 8-K · Current report | Jun 15, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | May 22, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Apr 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 28, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 6, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 6, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 6, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 17, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 17, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 30, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 9, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 2, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 28, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 20, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Oct 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 8, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 16, 2025 | Offer document | SEC |
| 4/A · Change in ownership, amended | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 8-K · Current report | May 27, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Apr 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 29, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 8, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 8, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 8, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Mar 31, 2025 | Management or board change | SEC |
| 8-K/A · Current report, amended | Mar 19, 2025 | Management or board change | SEC |
| 8-K · Current report | Mar 18, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 18, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 10-K · Annual report | Feb 18, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 18, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 15, 2025 | Management or board change | SEC |
| 8-K · Current report | Jan 10, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 4, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 4, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 15, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2024 | Results | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 30, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2024 | Results | SEC |
| S-8 · Registration statement for employee plans | Jun 13, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 28, 2024 | Other filings | SEC |
| 8-K · Current report | May 24, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from NeoGenomics, Inc.’s releases · as of Oct 23, 2026
- Common shares
- 129,389,465
- Fully diluted
- 129,389,465
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 129,389,465 | Oct 23, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 23, 2026 | 129,389,465 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christopher M Smith Other companies: Pacific Biosciences of California, Inc. (Director · Since at least Jan 30, 2025); QuidelOrtho Corporation (Director · May 27, 2022 – Jun 6, 2023 · Past); Ortho Clinical Diagnostics Holdings plc (Chairman and CEO, Director · Jan 27, 2021 – May 27, 2022 · Past); Akouos Inc (Director · Jun 25, 2020 – Jun 23, 2022 · Past); StarTek Inc (Director · Jun 7, 2010 – Oct 1, 2011 · Past) | Chief Executive Officer · Aug 15, 2022 – Feb 23, 2025 · Past |
| Halley E. Gilbert Other companies: Vaxcyte, Inc. (Director · Since at least Jun 11, 2020); Arcutis Biotherapeutics, Inc. (Director · Since at least May 1, 2020); CytomX Therapeutics, Inc. (Director · Since at least Apr 27, 2020); Achaogen Inc (Director · Jan 4, 2017 – Jun 5, 2018 · Past); Ironwood Pharmaceuticals, Inc. (Chief Admin Officer & SVP · Mar 4, 2014 – Feb 21, 2020 · Past) | Chief Legal Officer · Aug 17, 2021 – Mar 1, 2022 · Past |
| Michael A. Kelly Other companies: Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Amicus Therapeutics Inc (Director · Since at least Dec 1, 2020); DMC Global Inc. (Director · Since at least Jul 24, 2020); Aprea Therapeutics, Inc. (Director · Sep 28, 2020 – Jun 30, 2021 · Past); Hookipa Pharma Inc (Director · Apr 17, 2019 – Jun 30, 2022 · Past) | Board Member · Since at least Jul 15, 2020 |
| Felicia Williams Other companies: Anywhere Real Estate Inc (Director · Since at least Mar 18, 2021); Paycom Software, Inc. (Director · May 9, 2022 – May 5, 2025 · Past); Meridian Bioscience Inc (Director · Sep 20, 2018 – Jan 31, 2023 · Past); Macy's Inc (SVP,Controller/ERM & Int. CFO · Jun 1, 2016 – Jul 9, 2020 · Past) | Board Member · Since at least Nov 1, 2024 |
| Jack Kenny Other companies: OraSure Technologies, Inc. (Director · Since at least Sep 6, 2024); Quantum-Si Incorporated (Director · Since at least May 19, 2023); Biomerica, Inc. (Director · Aug 28, 2023 – Dec 13, 2023 · Past); Meridian Bioscience Inc (Chief Executive Officer, Director · Oct 9, 2017 – Jan 31, 2023 · Past) | Director · Since at least Jan 1, 2026 |
| Anthony P Zook Other companies: Streamex Corp. (Director · Jul 1, 2020 – Dec 28, 2021 · Past); Innocoll AG (CEO, Director · Jan 1, 2017 – Jul 24, 2017 · Past); VIVUS Inc (Chief Executive Officer, Director · Jul 22, 2013 – Jul 25, 2013 · Past) | Chief Executive Officer, Director · Since at least Jun 26, 2023 |
| Lynn A. Tetrault Other companies: Alumis Inc. (Director · Since at least May 21, 2025); Rhythm Pharmaceuticals, Inc. (Director · Since at least Dec 9, 2020); Acelyrin, Inc. (Director · Dec 18, 2023 – May 21, 2025 · Past) | Director · Since at least Jun 2, 2021 |
| Alison L Hannah Other companies: Rigel Pharmaceuticals, Inc. (EVP, Chief Medical Officer · Since at least May 14, 2021); CytomX Therapeutics, Inc. (Chief Medical Officer · Feb 3, 2020 – Jul 19, 2022 · Past) | Director · Since at least Jun 12, 2015 |
| David Daly Other companies: Singular Genomics Systems Inc (President and Chief Operating · May 26, 2021 – Mar 4, 2022 · Past); Foundation Medicine Inc (Chief Commercial Officer · Dec 2, 2014 – Aug 9, 2017 · Past) | Director · Nov 10, 2021 – Jun 10, 2022 · Past |
| David Perez Other companies: Ortho Clinical Diagnostics Holdings plc (Director · Jan 27, 2021 – May 27, 2022 · Past); Mesa Laboratories, Inc. (Director · Jan 23, 2019 – Jun 17, 2020 · Past) | Board Member · Since at least Nov 3, 2022 |
All 53 people
| Person | Seat |
|---|---|
| Jeffrey Scott Sherman Other companies: Privia Health Group, Inc. (EVP, CFO and CAO · Jan 5, 2022 – Jan 5, 2022 · Past); HMS Holdings Corp (EVP, CFO, and Treasurer · Aug 13, 2015 – Apr 1, 2021 · Past) | Chief Financial Officer · Since at least Dec 5, 2022 |
| Sharon Virag Other companies: Aetna Inc (VP, Controller & CAO · Jul 3, 2015 – Jun 12, 2017 · Past); The AES Corporation (VP, Controller · May 13, 2013 – May 13, 2015 · Past) | Chief Financial Officer · Mar 27, 2018 – Mar 1, 2019 · Past |
| Abhishek Jain Other companies: CareDx, Inc. (Chief Financial Officer · Since at least May 26, 2022) | Chief Financial Officer · Since at least Jan 12, 2026 |
| George Cardoza Other companies: Sophia Genetics SA (EVP – Chief Financial Officer · Since at least Nov 5, 2024) | President & COO, Lab Ops · May 2, 2011 – Mar 1, 2022 · Past |
| Greg D Aunan Other companies: HMS Holdings Corp (SVP, Chief Accounting Officer · Jun 29, 2015 – Apr 1, 2021 · Past) | Chief Accounting Officer · Since at least May 15, 2023 |
| Jerome J Dvonch Other companies: Sonoma Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Sep 8, 2020) | Prinicpal Accounting Officer · May 2, 2011 – May 2, 2011 · Past |
| Mark Mallon Other companies: Ironwood Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jan 4, 2019 – Feb 26, 2021 · Past) | Chief Executive Officer, Director · Apr 19, 2021 – Mar 1, 2022 · Past |
| Rachel Stahler Other companies: Organon & Co. (Chief Digital and Growth Officer · Since at least Jun 2, 2021) | Director · May 28, 2020 – Jun 10, 2022 · Past |
| Vishal Sikri Other companies: Myriad Genetics, Inc. (Executive Vice President - Commercial · Since at least Sep 16, 2026) | President Advanced Diagnostics · May 23, 2022 – Feb 23, 2024 · Past |
| William J Robison Other companies: MWI Veterinary Supply Inc (Director · Aug 17, 2009 – Feb 23, 2015 · Past) | Director · May 2, 2011 – May 25, 2017 · Past |
| Alicia C Olivo | EVP, GC & Business Development · Since at least Sep 30, 2023 |
| Andrew Lukowiak | Chief Innovation Officer · Since at least Apr 22, 2025 |
| Carolyn Starrett | Director · Since at least Jun 23, 2026 |
| Clarence Cooper | Vice President, Compliance & Privacy · Since at least Nov 4, 2026 |
| Clive Morris | President of Inivata · Jun 18, 2021 – Dec 30, 2021 · Past |
| David Sholehvar | President, Clinical Services · Mar 14, 2022 – Aug 1, 2022 · Past |
| Douglas Matthew Brown | Chief Strategy Officer · Feb 23, 2021 – Apr 1, 2022 · Past |
| Elizabeth Floegel | Chief Digital and Information Officer · Since at least Jun 26, 2023 |
| Ellisa Cholapranee | General Counsel · Since at least Nov 4, 2026 |
| Gary Passman | Chief Culture Officer · Since at least Nov 4, 2026 |
| Gina M Wallar | President, Pharma Services · Jul 5, 2021 – Mar 1, 2022 · Past |
| Jack Kenny | Board Member · Since at least Dec 30, 2025 |
| Jennifer Balliet | VP and Chief Culture Officer · Apr 20, 2016 – Dec 30, 2021 · Past |
| Kathryn B McKenzie | Chief Sustainability/Risk Ofcr · Oct 17, 2017 – Jan 11, 2022 · Past |
| Kevin C Johnson | Director · May 3, 2011 – Dec 22, 2021 · Past |
| Kristi McKeown | Chief Commercial Officer · Since at least Nov 4, 2026 |
| Lawrence Martin Weiss | Chief Medical Officer · Dec 14, 2020 – Apr 22, 2021 · Past |
| Marjorie Green | Board Member · Since at least Jun 19, 2025 |
| Mark Alan Machulcz | Vice President of Operations · Jan 28, 2016 – Jan 28, 2016 · Past |
| Mark W Smits | Chief Commercial Officer · May 2, 2011 – May 18, 2011 · Past |
| Marydawn Miller | Vice President of IT · May 2, 2011 – May 2, 2011 · Past |
| Melody Harris | Chf Ops Off, Pres, Informatics · Dec 5, 2022 – Feb 21, 2025 · Past |
| Nathan Montgomery | Vice President, Medical Services · Since at least Jul 9, 2026 |
| Neil Gunn | Board Member · Since at least Jun 26, 2023 |
| Raymond R Hipp | Director · Jun 1, 2018 – Nov 16, 2020 · Past |
| Robert H Horel | Vice President GM PathLogic · Dec 18, 2014 – Dec 29, 2015 · Past |
| Stephanie K Bywater | Chief Compliance Officer · May 1, 2018 – May 1, 2018 · Past |
| Stephen Kanovsky | Board Member · Since at least Jul 19, 2017 |
| Steven A Ross | CIO · Nov 18, 2013 – May 10, 2018 · Past |
| Steven G Brodie | VP - Pharma Operations · Apr 16, 2015 – Oct 22, 2018 · Past |
| Tony Zook | Chief Executive Officer · Since at least Apr 3, 2026 |
| Warren Stone | President and Chief Operating Officer · Since at least Nov 21, 2022 |
| William Bonello | Chief Financial Officer · May 6, 2019 – Apr 28, 2022 · Past |
Log in to ask 6ix AI your own questions about NeoGenomics, Inc.